tetano
Editor, Senior Moderator
Blood Purif
. 2020 Oct 8;1-3.
doi: 10.1159/000511392. Online ahead of print.
Sudden Cardiac Death in Haemodialysis Patients under Hydroxychloroquine Treatment for COVID-19: A Report of Two Cases
Ahmet Murt[SUP] 1 [/SUP], Mevlut Tamer Dincer[SUP] 2 [/SUP], Cebrail Karaca[SUP] 2 [/SUP]
Affiliations
Abstract
Hydroxychloroquine (HQ) has been used for the treatment of novel coronavirus disease (COVID-19) even though there is no clear evidence for its effectiveness yet. In contrary, HQ has major side effects like QTc prolongation and subsequent development of ventricular arrhythmias. Such side effects may possess additional risks on end-stage renal disease (ESRD) patients who have higher cardiovascular risks than general population. We herein present 2 cases of sudden cardiac death in 2 ESRD patients with COVID-19 for whom a treatment regimen including HQ was preferred. Both patients were clinically stable at the time of arrest. Death could not be attributed to worsening of the COVID-19 since the patients' clinical picture and laboratory values were improving. The cardiac events coincided with the end of routine haemodialysis sessions of both patients. Electrocardiography controls upon admission and on the 24 and 48 h of treatment showed normal QTc intervals. Potential risks contributing to sudden cardiac death during HQ treatment of ESRD patients are discussed.
Keywords: Coronavirus disease-19; End-stage renal disease; Haemodialysis; Hydroxychloroquine; Sudden death.
. 2020 Oct 8;1-3.
doi: 10.1159/000511392. Online ahead of print.
Sudden Cardiac Death in Haemodialysis Patients under Hydroxychloroquine Treatment for COVID-19: A Report of Two Cases
Ahmet Murt[SUP] 1 [/SUP], Mevlut Tamer Dincer[SUP] 2 [/SUP], Cebrail Karaca[SUP] 2 [/SUP]
Affiliations
- PMID: 33032282
- DOI: 10.1159/000511392
Abstract
Hydroxychloroquine (HQ) has been used for the treatment of novel coronavirus disease (COVID-19) even though there is no clear evidence for its effectiveness yet. In contrary, HQ has major side effects like QTc prolongation and subsequent development of ventricular arrhythmias. Such side effects may possess additional risks on end-stage renal disease (ESRD) patients who have higher cardiovascular risks than general population. We herein present 2 cases of sudden cardiac death in 2 ESRD patients with COVID-19 for whom a treatment regimen including HQ was preferred. Both patients were clinically stable at the time of arrest. Death could not be attributed to worsening of the COVID-19 since the patients' clinical picture and laboratory values were improving. The cardiac events coincided with the end of routine haemodialysis sessions of both patients. Electrocardiography controls upon admission and on the 24 and 48 h of treatment showed normal QTc intervals. Potential risks contributing to sudden cardiac death during HQ treatment of ESRD patients are discussed.
Keywords: Coronavirus disease-19; End-stage renal disease; Haemodialysis; Hydroxychloroquine; Sudden death.